Table 1.
Baseline characteristics of patients.
| Characteristics | Control group (n=21) | Telephone group (n=21) | TECCUa group (n=21) | |
| Median age, years (range) | 39.31 (22-61) | 40.91 (24-60) | 41.32 (19-66) | |
| Sex, n (%) |
|
|
|
|
|
|
Men | 12 (57.1%) | 12 (57.1%) | 9 (42.9%) |
|
|
Women | 9 (42.9%) | 9 (42.9%) | 12 (57.1%) |
| Education, n (%) |
|
|
|
|
|
|
Primary | 4/21 (19%) | 4/21 (19%) | 5/21 (23.8%) |
|
|
Secondary | 9/21 (42.9%) | 6/21 (28.6%) | 6/21 (28.6%) |
|
|
University | 8/21 (38.1%) | 11/21 (52.4%) | 10/21 (47.6%) |
| Disease profile |
|
|
|
|
|
|
Crohn disease, n (%) | 14/21 (66.7%) | 13/21 (61.9%) | 13/21 (61.9%) |
|
|
Ulcerative colitis, n (%) | 7/21 (33.3%) | 8/21 (38.1%) | 8/21 (38.1%) |
| Median time since diagnosis, months (range) | 123.32 (6-427) | 108.27 (7-452) | 146.72 (7-424) | |
| Treatment (%) |
|
|
|
|
|
|
Immunomodulators | 10/21 (47.6%) | 10/21 (47.6%) | 9/21 (42.9%) |
|
|
Biological monotherapy | 4/21 (19%) | 4/21 (19%) | 4/21 (19%) |
|
|
Combination therapy | 6/21 (28.6%) | 5/21 (23.8%) | 6/21 (28.6%) |
|
|
Corticosteroids | 1/21 (4.8%) | 2/21 (9.5%) | 2/21 (9.5%) |
| Clinical Remission, n (%) | 12/21 (57.1%) | 8/21 (38.1%) | 10/21 (47.6%) | |
|
|
Crohn disease | 10/14 (71.4%) | 6/13 (46.2%) | 9/13 (69.2%) |
|
|
Ulcerative colitis | 2/7 (28.6%) | 2/8 (25%) | 1/8 (12.5%) |
| Median calprotectin level, μg/g (interquartile range) | 330 (103-617) | 526 (115-1724) | 490 (23-2016) | |
| Quality of life |
|
|
|
|
|
|
Median IBDQ-9b score (interquartile range) | 38.50 (33.25-46.75) | 37.50 (28.75-46.25) | 42.00 (33.75-47.50) |
|
|
Median EQ-5Dc score (interquartile range) | 0.816 (0.754-0.914) | 0.825 (0.710-0.914) | 0.825 (0.576-0.914) |
|
|
Median VASd, % (interquartile range) | 60.5% (50%-85%) | 62.5% (50%-80%) | 60% (40%-90%) |
| Medication adherence, n (%) | 14/21 (66.7%) | 7/21 (33,3%) | 12/21 (57,1%) | |
| WPAIe |
|
|
|
|
|
|
Not working, n (%) | 8/21 (38.1%) | 7/21 (33.3%) | 5/21 (23.8%) |
|
|
Percentage of work hours missed, median (interquartile range) | 27.5% (0%-52%) | 40% (15%-62.5%) |
32.5% (7.5%-57.5%) |
|
|
Work impairment score, median (interquartile range) | 7 (2.75-10) | 7 (3-10) |
10 (2.25-10) |
|
|
Social impairment score, median (interquartile range) | 3.5 (1-5.75) | 3.5 (2-7) | 6 (2.75-8) |
| Satisfaction score, median (interquartile range) | 49.5 (42.5-53.75) | 53 (50-59) | 52 (47.5-55) | |
aTECCU: Telemonitoring of Crohn’s Disease and Ulcerative Colitis.
bIBDQ-9: Inflammatory Bowel Disease Questionnaire 9.
cEQ-5D: EuroQol-5D.
dVAS: visual analog scale.
eeWPAI: Work Productivity and Activity Impairment.